Prevention of new-onset chronic kidney disease with renin-angiotensin system blockers in type 2 diabetes with preserved kidney function.
ACEI/ARB therapy was associated with a 28% lower risk of new-onset chronic kidney disease in patients with type 2 diabetes and preserved kidney function.
Where it sits
this study against the rest of the liraglutide corpusSummary and findings
This study evaluated the impact of renin-angiotensin system blockers on the onset of chronic kidney disease in patients with type 2 diabetes and preserved kidney function. A total of 4,725 individuals were analyzed, comparing 3,316 ACEI/ARB users to 1,409 nonusers. The study found that ACEI/ARB therapy was associated with a lower risk of new-onset CKD.
Abstract
Renin-angiotensin system (RAS) blockers, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are known to slow chronic kidney disease (CKD) progression in patients with established renal impairment. However, whether RAS blockade can prevent new-onset CKD in patients with type 2 diabetes and hypertension who maintain preserved kidney function remains unclear. We addressed this question in a multicenter retrospective cohort study. Beginning with 316,693 individuals with type 2 diabetes and newly diagnosed hypertension, we retained 3,316 ACEI/ARB users and 1,409 nonusers after generalized boosted model weighting to equalize baseline characteristics. Three renal endpoints were followed: a sustained eGFR below 60 mL/min/1.73 m2, incident albuminuria (urinary albumin-to-creatinine ratio of 30 mg/g or higher), and a composite of either. Associations between RAS blocker exposure and each endpoint were quantified using Cox proportional hazards regression, with competing-risk and time-dependent variants applied as confirmatory analyses. ACEI/ARB therapy was associated with a significantly lower risk of new-onset CKD (HR 0.72; 95% CI 0.60-0.86), with consistent findings after accounting for competing risks (HR 0.73; 95% CI 0.61-0.87) and time-dependent exposure (HR 0.81; 95% CI 0.68-0.96). These findings suggest that RAS blockade may confer early kidney protection in patients with type 2 diabetes and hypertension with preserved renal function.
Background
This paper addresses the potential role of renin-angiotensin system blockers in preventing new-onset chronic kidney disease (CKD) in patients with type 2 diabetes and preserved kidney function. Previous research has established that RAS blockers can slow CKD progression in those with existing renal impairment, but their preventive effects in this specific population remain uncertain. Understanding this relationship is crucial for optimizing treatment strategies in diabetic patients at risk for kidney disease.
Methods
The study utilized a multicenter retrospective cohort design, beginning with 316,693 individuals diagnosed with type 2 diabetes and newly diagnosed hypertension. After applying generalized boosted model weighting to equalize baseline characteristics, 3,316 ACEI/ARB users and 1,409 nonusers were included in the analysis. The primary outcomes were three renal endpoints: sustained eGFR below 60 mL/min/1.73 m², incident albuminuria, and a composite of either.
Results
The primary endpoint showed that ACEI/ARB therapy was associated with a significantly lower risk of new-onset CKD, with a hazard ratio of 0.72 (95% CI 0.60-0.86). This finding was consistent after adjusting for competing risks (HR 0.73; 95% CI 0.61-0.87) and when considering time-dependent exposure (HR 0.81; 95% CI 0.68-0.96).
Interpretation
These results suggest that RAS blockade may provide early kidney protection in patients with type 2 diabetes and hypertension. While the findings are statistically significant, the clinical significance should be carefully considered, especially given the observational nature of the study and potential confounding factors. The retrospective design limits the ability to draw definitive conclusions about causality.
Key findings
- HR 0.72; 95% CI 0.60-0.86 for new-onset CKD with ACEI/ARB therapy.
- HR 0.73; 95% CI 0.61-0.87 after accounting for competing risks.
- HR 0.81; 95% CI 0.68-0.96 for time-dependent exposure.
Limitations
- retrospective cohort design
- potential confounding factors
- not randomized
- single-site data may limit generalizability